Your browser doesn't support javascript.
loading
The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers.
Gasca-Capote, Carmen; Lian, Xiaodong; Gao, Ce; Roseto, Isabelle C; Jiménez-León, María Reyes; Gladkov, Gregory; Camacho-Sojo, María Inés; Pérez-Gómez, Alberto; Gallego, Isabel; Lopez-Cortes, Luis E; Bachiller, Sara; Vitalle, Joana; Rafii-El-Idrissi Benhnia, Mohamed; Ostos, Francisco J; Collado-Romacho, Antonio R; Santos, Jesús; Palacios, Rosario; Gomez-Ayerbe, Cristina; Muñoz-Medina, Leopoldo; Ruiz-Sancho, Andrés; Frias, Mario; Rivero-Juarez, Antonio; Roca-Oporto, Cristina; Hidalgo-Tenorio, Carmen; Rull, Anna; Olalla, Julian; Lopez-Ruz, Miguel A; Vidal, Francesc; Viladés, Consuelo; Mastrangelo, Andrea; Cavassini, Matthias; Espinosa, Nuria; Perreau, Matthieu; Peraire, Joaquin; Rivero, Antonio; López-Cortes, Luis F; Lichterfeld, Mathias; Yu, Xu G; Ruiz-Mateos, Ezequiel.
Afiliação
  • Gasca-Capote C; Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital, Spanish National Research Council (CSIC), University of Seville, Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Seville, Spain.
  • Lian X; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
  • Gao C; Infectious Disease Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Roseto IC; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
  • Jiménez-León MR; Infectious Disease Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Gladkov G; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
  • Camacho-Sojo MI; Infectious Disease Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Pérez-Gómez A; Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital, Spanish National Research Council (CSIC), University of Seville, Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Seville, Spain.
  • Gallego I; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
  • Lopez-Cortes LE; Infectious Disease Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Bachiller S; Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital, Spanish National Research Council (CSIC), University of Seville, Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Seville, Spain.
  • Vitalle J; Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital, Spanish National Research Council (CSIC), University of Seville, Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Seville, Spain.
  • Rafii-El-Idrissi Benhnia M; Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital, Spanish National Research Council (CSIC), University of Seville, Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Seville, Spain.
  • Ostos FJ; Clinical Unit of Infectious Diseases and Microbiology, Virgen Macarena University Hospital, Seville, Spain.
  • Collado-Romacho AR; Department of Medicine and Microbiology, School of Medicine and.
  • Santos J; IBiS, Virgen Macarena University Hospital, CSIC, University of Seville, Seville, Spain.
  • Palacios R; CIBERINFEC, Institute of Health Carlos III (ISCIII), Madrid, Spain.
  • Gomez-Ayerbe C; Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital, Spanish National Research Council (CSIC), University of Seville, Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Seville, Spain.
  • Muñoz-Medina L; Department of Medical Biochemistry, Molecular Biology, and Immunology, School of Medicine, University of Seville, Seville, Spain.
  • Ruiz-Sancho A; Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital, Spanish National Research Council (CSIC), University of Seville, Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Seville, Spain.
  • Frias M; Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital, Spanish National Research Council (CSIC), University of Seville, Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Seville, Spain.
  • Rivero-Juarez A; Department of Medical Biochemistry, Molecular Biology, and Immunology, School of Medicine, University of Seville, Seville, Spain.
  • Roca-Oporto C; Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital, Spanish National Research Council (CSIC), University of Seville, Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Seville, Spain.
  • Hidalgo-Tenorio C; Department of Medical Biochemistry, Molecular Biology, and Immunology, School of Medicine, University of Seville, Seville, Spain.
  • Rull A; Infectious Diseases Unit, Internal Medicine Service, Torrecardenas University Hospital, Almeria, Spain.
  • Olalla J; Infectious Diseases, Microbiology and Preventive Medicine Unit, Virgen de la Victoria University Hospital, Malaga, Spain.
  • Lopez-Ruz MA; Infectious Diseases, Microbiology and Preventive Medicine Unit, Virgen de la Victoria University Hospital, Malaga, Spain.
  • Vidal F; Infectious Diseases, Microbiology and Preventive Medicine Unit, Virgen de la Victoria University Hospital, Malaga, Spain.
  • Viladés C; Unit of Infectious Diseases, San Cecilio University Hospital, Biohealth Research Institute, IBS-Granada, Granada, Spain.
  • Mastrangelo A; Unit of Infectious Diseases, San Cecilio University Hospital, Biohealth Research Institute, IBS-Granada, Granada, Spain.
  • Cavassini M; CIBERINFEC, Institute of Health Carlos III (ISCIII), Madrid, Spain.
  • Espinosa N; Service of Infectious Diseases, Reina Sofía University Hospital, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba University, Cordoba, Spain.
  • Perreau M; CIBERINFEC, Institute of Health Carlos III (ISCIII), Madrid, Spain.
  • Peraire J; Service of Infectious Diseases, Reina Sofía University Hospital, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba University, Cordoba, Spain.
  • Rivero A; Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital, Spanish National Research Council (CSIC), University of Seville, Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Seville, Spain.
  • López-Cortes LF; Unit of Infectious Diseases, Virgen de las Nieves University Hospital, Biohealth Research Institute, IBS-Granada, Granada, Spain.
  • Lichterfeld M; CIBERINFEC, Institute of Health Carlos III (ISCIII), Madrid, Spain.
  • Yu XG; Joan XXIII University Hospital of Tarragona, IISPV, University of Rovira i Virgili, Tarragona, Spain.
  • Ruiz-Mateos E; Internal Medicine Department, Costa Del Sol Hospital, Marbella, Spain.
J Clin Invest ; 134(8)2024 Feb 20.
Article em En | MEDLINE | ID: mdl-38376918
ABSTRACT
BACKGROUNDPersistent controllers (PCs) maintain antiretroviral-free HIV-1 control indefinitely over time, while transient controllers (TCs) eventually lose virological control. It is essential to characterize the quality of the HIV reservoir in terms of these phenotypes in order to identify the factors that lead to HIV progression and to open new avenues toward an HIV cure.METHODSThe characterization of HIV-1 reservoir from peripheral blood mononuclear cells was performed using next-generation sequencing techniques, such as full-length individual and matched integration site proviral sequencing (FLIP-Seq; MIP-Seq).RESULTSPCs and TCs, before losing virological control, presented significantly lower total, intact, and defective proviruses compared with those of participants on antiretroviral therapy (ART). No differences were found in total and defective proviruses between PCs and TCs. However, intact provirus levels were lower in PCs compared with TCs; indeed the intact/defective HIV-DNA ratio was significantly higher in TCs. Clonally expanded intact proviruses were found only in PCs and located in centromeric satellite DNA or zinc-finger genes, both associated with heterochromatin features. In contrast, sampled intact proviruses were located in permissive genic euchromatic positions in TCs.CONCLUSIONSThese results suggest the need for, and can give guidance to, the design of future research to identify a distinct proviral landscape that may be associated with the persistent control of HIV-1 without ART.FUNDINGInstituto de Salud Carlos III (FI17/00186, FI19/00083, MV20/00057, PI18/01532, PI19/01127 and PI22/01796), Gilead Fellowships (GLD22/00147). NIH grants AI155171, AI116228, AI078799, HL134539, DA047034, MH134823, amfAR ARCHE and the Bill and Melinda Gates Foundation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article